🎉 M&A multiples are live!
Check it out!

Nuvectis Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Nuvectis Pharma and similar public comparables like Vivoryon Therapeutics, Benevolent AI, and Julphar.

Nuvectis Pharma Overview

About Nuvectis Pharma

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.


Founded

2020

HQ

United States of America
Employees

13

Website

nuvectis.com

Financials

LTM Revenue n/a

LTM EBITDA -$22.2M

EV

$210M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Nuvectis Pharma Financials

Nuvectis Pharma has a last 12-month revenue of n/a and a last 12-month EBITDA of -$22.2M.

In the most recent fiscal year, Nuvectis Pharma achieved revenue of n/a and an EBITDA of -$19.8M.

Nuvectis Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Nuvectis Pharma valuation multiples based on analyst estimates

Nuvectis Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$22.9M -$19.8M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$19.1M -$22.3M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Nuvectis Pharma Stock Performance

As of April 15, 2025, Nuvectis Pharma's stock price is $10.

Nuvectis Pharma has current market cap of $229M, and EV of $210M.

See Nuvectis Pharma trading valuation data

Nuvectis Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$210M $229M XXX XXX XXX XXX $-1.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Nuvectis Pharma Valuation Multiples

As of April 15, 2025, Nuvectis Pharma has market cap of $229M and EV of $210M.

Nuvectis Pharma's trades at n/a LTM EV/Revenue multiple, and -9.5x LTM EBITDA.

Analysts estimate Nuvectis Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Nuvectis Pharma and 10K+ public comps

Nuvectis Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $210M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -10.6x XXX XXX XXX
P/E -12.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -17.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Nuvectis Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Nuvectis Pharma Valuation Multiples

Nuvectis Pharma's NTM/LTM revenue growth is n/a

Nuvectis Pharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.5M for the same period.

Over next 12 months, Nuvectis Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Nuvectis Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Nuvectis Pharma and other 10K+ public comps

Nuvectis Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -13% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Nuvectis Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Small Molecules comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Nuvectis Pharma M&A and Investment Activity

Nuvectis Pharma acquired  XXX companies to date.

Last acquisition by Nuvectis Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Nuvectis Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Nuvectis Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Nuvectis Pharma

When was Nuvectis Pharma founded? Nuvectis Pharma was founded in 2020.
Where is Nuvectis Pharma headquartered? Nuvectis Pharma is headquartered in United States of America.
How many employees does Nuvectis Pharma have? As of today, Nuvectis Pharma has 13 employees.
Who is the CEO of Nuvectis Pharma? Nuvectis Pharma's CEO is Mr. Ron Bentsur.
Is Nuvectis Pharma publicy listed? Yes, Nuvectis Pharma is a public company listed on NAS.
What is the stock symbol of Nuvectis Pharma? Nuvectis Pharma trades under NVCT ticker.
When did Nuvectis Pharma go public? Nuvectis Pharma went public in 2022.
Who are competitors of Nuvectis Pharma? Similar companies to Nuvectis Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Nuvectis Pharma? Nuvectis Pharma's current market cap is $229M
What is the current EBITDA of Nuvectis Pharma? Nuvectis Pharma's last 12-month EBITDA is -$22.2M.
What is the current EV/EBITDA multiple of Nuvectis Pharma? Current EBITDA multiple of Nuvectis Pharma is -9.5x.
Is Nuvectis Pharma profitable? Yes, Nuvectis Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.